Skip to main content
Terug
FDMT logo

4D Molecular Therapeutics, Inc.

Datakwaliteit: 100%
FDMT
NASDAQ Healthcare Biotechnology
€ 9,88
▲ € 0,70 (7,63%)
Marktkapitalisatie: 504,39M
Dagbereik
€ 9,34 € 10,24
52-Weeksbereik
€ 2,24 € 12,34
Volume
883.954
50D / 200D Gem.
€ 8,71 / € 7,86
Vorige Slotkoers
€ 9,18

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E -3,6 0,2
P/B 1,0 3,0
ROE % -27,6 3,6
Net Margin % -164,4 3,8
Rev Growth 5Y % 47,4 9,9
D/E 0,0 0,2

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 47,43% annually over 5 years — strong growth
Debt/Equity of 0,04 — conservative balance sheet
Negative free cash flow of -109,08M
PEG of 0,17 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 230147,16%
Capital efficient — spends only 0,63% of revenue on capex

Groei

Revenue Growth (5Y)
47,43%
Revenue (1Y)230194,59%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-27,57%
ROIC-22,70%
Net Margin-164,43%
Op. Margin-187,24%

Veiligheid

Debt / Equity
0,04
Current Ratio9,39
Interest Coverage0,00

Waardering

P/E Ratio
-3,60
Forward P/EN/A
P/B Ratio1,00
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 230194,59% Revenue Growth (3Y) 102,78%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 47,43% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 85,21M Net Income (TTM) -140,11M
ROE -27,57% ROA -24,72%
Gross Margin 91,05% Operating Margin -187,24%
Net Margin -164,43% Free Cash Flow (TTM) -109,08M
ROIC -22,70% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,04 Current Ratio 9,39
Interest Coverage 0,00
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,60 Forward P/E N/A
P/B Ratio 1,00 P/S Ratio 5,92
PEG Ratio 0,17 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -21,63%
Market Cap 504,39M Enterprise Value 465,56M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 85,21M 37.000,0 20,72M 3,13M 18,04M
Net Income -140,11M -160,87M -100,84M -107,49M -71,32M
EPS (Diluted) -2,42 -2,98 -2,58 -3,12 -2,46
Gross Profit 77,58M 37.000,0 -76,37M -77,12M -43,32M
Operating Income -159,55M -187,84M -112,87M -110,03M -71,33M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 566,71M 560,38M 339,89M 261,85M 353,49M
Total Liabilities 61,05M 49,78M 32,06M 30,51M 34,38M
Shareholders' Equity 505,66M 510,61M 307,83M 231,34M 319,11M
Total Debt 21,41M 24,61M 14,67M 16,12M 16,45M
Cash & Equivalents 60,24M 149,34M 249,11M 52,35M 153,00M
Current Assets 413,13M 434,93M 296,59M 220,51M 256,28M
Current Liabilities 43,99M 29,15M 18,95M 15,73M 16,34M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#44 of 148
55

Recente Activiteit

Ingestapt Full Throttle
Mar 26, 2026